Cold Genesys’s oncolytic virus: phase 3 ready with positive efficacy and safety data in bladder cancer

Cold Genesys is developing CG0070, a promising oncolytic virus that is proving successful in trials as a single agent, with near-term plans to develop it in combination with immuno-oncology agents.

Like Comment
Page of
Go to the profile of Cold Genesys

Cold Genesys

Cold Genesys in a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies. Our strategy is centered on providing patients with new and impactful therapies. Our lead proprietary agent, CG0070, has the potential to deliver safe and effective cancer care alone and in combination with other immunotherapies. CG0070 has been shown to be a safe agent in BCG-failure non-muscle invasive bladder cancer (NMIBC) and we are exploring further types of cancer in clinical studies. We aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.

No comments yet.